Debiopharm Ignites Oncology Innovation With Clinical and Translational Data on Debio 0123 at the 2025 ASCO Annual Meeting in Chicago
Debiopharm announces an abstract publication and three poster presentations on Debio 0123, a highly selective WEE1 inhibitor, in multiple solid tumor indications.
LAUSANNE, Switzerland, May 29, 2025--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standard-of-care to cure cancer and infectious diseases, today unveiled its upcoming contributions to the 2025 Annual American Society of Clinical Oncology (ASCO) Meeting in Chicago, Illinois.
The contributions feature three clinical poster presentations and one translational research abstract publication, highlighting Debio 0123's potential across solid tumors. Among them is new data from the Debio 0123-SCLC-104 trial in small-cell lung cancer, offering insights into the candidate's therapeutic potential in this difficult-to-treat disease. A Trial in Progress (TiP) poster from the investigator-initiated MedSir study—co-authored by Debiopharm—will present the design and methodology of the study investigating the combination of Debio 0123 with Trodelvy® in breast cancer patients. In parallel, a separate TiP poster for the Debio 0123-102 monotherapy study will outline the framework and objectives of the ongoing dose expansion phase.
"Presenting our latest data on Debio 0123 at ASCO 2025 is a proud milestone for our team," said Angela Zubel, Chief Development Officer at Debiopharm. "This research highlights the promise of WEE1 inhibition as a precision strategy to target the vulnerabilities of aggressive cancers. Our goal is to push the boundaries of innovation to bring transformative therapies to patients who urgently need new options."
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
ASCO 2025 Contribution
Title
Presenter/Author
Abstract #e15127
*Publication only
In silico evaluation of the interaction of P-gp and 3A4 substrates with the WEE1 inhibitor Debio 0123 and clinical application in the Debio 0123-104 combination trial with carboplatin and etoposide.
Anne Bellon, PhD, PharmD
Debiopharm
Abstract #TPS3172
Poster Bd #: 479b
Phase IB/II study to evaluate safety and preliminary efficacy of the WEE1 inhibitor Debio 0123 in combination with sacituzumab govitecan (SG) in triple-negative or hormone receptor–positive (HR+)/HER2-negative (HER2–) advanced breast cancer (ABC): The WIN-B study.
Maria Gion, MD, PhD
Medical Oncologist at Ramón y Cajal University Hospital
*Medsir and Debiopharm
Session Title: Gynecologic Cancer
ASCO 2025 Contribution
Title
Presenter/Author
Abstract #TPS5634
Poster Bd #: 524a
Debio 0123, a highly selective WEE1 inhibitor in adult patients with advanced solid tumors: A phase 1 dose escalation and expansion monotherapy study.
Maria M. Rubinstein, MD
Memorial Sloan Kettering Cancer Center, New York, NY
Session Title: Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
ASCO 2025 Contribution
Title
Presenter/Author
Abstract #8098
Poster Bd #: 219
Debio 0123, a highly selective WEE1 inhibitor, in combination with carboplatin (C) and etoposide (E), in patients (pts) with recurrent small cell lung cancer (SCLC): Determination of recommended dose (RD) from a phase 1 escalation.
Valentina Gambardella, MD, PhD
Department of Medical Oncology, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain
About DNA-Damage Repair (DDR)
When cells have damaged DNA, they need to undergo a repair process called DDR to be able to survive. Cancer cells rely heavily on DDR as they divide and grow uncontrollably. Inhibition of DDR, particularly in combination with other anticancer agents, prevents cancer cells from repairing their DNA, which ultimately activates a self-destruction program in cancer cells. DDR inhibitors such as Debiopharm's WEE1 inhibitor Debio 0123 are being tested in clinical and preclinical studies.
Debiopharm's commitment to patients
Debiopharm aims to develop innovative therapies that target high unmet medical needs primarily in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hand stewardship to large pharmaceutical commercialization partners to maximize patient access globally.
For more information, please visit www.debiopharm.com
Follow us on LinkedIn: www.linkedin.com/company/debiopharminternational
View source version on businesswire.com: https://www.businesswire.com/news/home/20250529299590/en/
Contacts
Debiopharm Contact Dawn BonineHead of Communicationsdawn.bonine@debiopharm.com Tel: +41 (0)21 321 01 11
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
29 minutes ago
- Business Wire
E3 Lithium Provides Progress Update for the Demonstration Facility
CALGARY, Alberta--(BUSINESS WIRE)--E3 LITHIUM LTD. (TSXV: ETL) (FSE: OW3) (OTCQX: EEMMF), 'E3', 'E3 Lithium' or the 'Company,' a leader in Canadian lithium, is pleased to provide a progress update on its Demonstration Facility ('Demo Facility'). The Demo Facility is planned to be brought on stream in three phases through the second half of 2025 and into 2026. The lithium extraction equipment comprising of the 30-column Direct Lithium Extraction (DLE) system (the '30-Column System'), as well as the purification and concentration equipment is now fully fabricated and undergoing final checks. The heart of the lithium production equipment is comprised of five separate skids, each containing a specific operation: Skids one and two host the 30-columns and the value control for the DLE system, skids 3 and 4 host the filtration and purification equipment and skid 5 houses the control center. The skids are expected to arrive and be assembled on site in the Clearwater Project area over the next six to eight weeks. E3 Lithium has also received the sorbent for the DLE columns and completed the majority of the payments for this equipment. Following arrival on site, the equipment will be assembled and undergo operational and safety checks, followed by final leak checks. Phase 1 will use brine hosted on site for the commissioning and operation of the 30-column system equipment to produce battery-grade lithium carbonate. It is expected that shortly after the drilling of the wells in Phase 2, the production well will be tied directly into the 30-column equipment and operate using a 'live' brine feed. Operation of a fully integrated system will enable E3 Lithium to optimize the process for factors such as recovery and flow rates and will provide important data for use in the design and costing of the commercial facility. The lithium carbonate produced will be used for customer interrogation and to potentially begin pre-qualification. Each phase of the Demo Facility is an important step towards validating the process technology and E3 Lithium's ability to produce battery-grade lithium carbonate from Leduc Brines at scale. The key objective of the Demo Facility is to de-risk the project design for E3 Lithium's full commercial scale Clearwater Project as the Company progresses towards completion of the Feasibility Study and securing of project financing. 'The team is very excited to see the equipment arrive on site,' commented E3 Lithium's CEO, Chris Doornbos. 'The Demo Facility will be one of the few systems of this kind globally to operate at this scale. It is a significant achievement for E3 Lithium to turn this design into a reality, and a major step forward to see it operate in the very near future.' Preparation for Phase 3 will increase as the first phase begins field operations and is expected to be installed in early 2026. ON BEHALF OF THE BOARD OF DIRECTORS Chris Doornbos, President & CEO E3 Lithium Ltd. About E3 Lithium E3 Lithium is a development company with a total of 16.2 million tonnes of lithium carbonate equivalent (LCE) Measured and Indicated 1 as well as 0.9 million tonnes LCE Inferred mineral resources 2 in Alberta and 2.5 million tonnes LCE Inferred mineral resources 3 in Saskatchewan. The Clearwater Pre-Feasibility Study outlined a 1.13 Mt LCE proven and probable mineral reserve with a pre-tax NPV8% of USD 5.2 Billion with a 29.2% IRR and an after-tax NPV8% of USD 3.7 Billion with a 24.6% IRR 1. 1: The Clearwater Project NI 43-101 Pre-Feasibility Study, effective June 20, 2024, is available on the E3 Lithium's website ( and SEDAR+ ( 2: The mineral resource NI 43-101 Technical Report for the North Rocky Property, effective October 27, 2017, identified 0.9 Mt LCE (inferred) and is available on the E3 Lithium's website ( and SEDAR+ ( 3: The mineral resource NI 43-101 Technical Report for the Estevan Lithium District, effective May 23, 2024, identified 2.5 Mt LCE (inferred) and is available on the E3 Lithium's website ( and SEDAR+ ( Unless otherwise indicated, Kevin Carroll, P. Eng., Chief Development Officer and a Qualified Person under National Instrument 43-101, has reviewed and is responsible for the technical information contained on this news release. Forward-Looking and Cautionary Statements This news release includes certain forward-looking statements as well as management's objectives, strategies, beliefs and intentions or forward-looking information within the meaning of applicable securities laws. Forward-looking statements are frequently identified by such words as 'believe', 'may', 'will', 'plan', 'expect', 'anticipate', 'estimate', 'intend', 'project', 'potential', 'possible' and similar words referring to future events and results. Forward-looking statements are based on the current opinions, expectations, estimates and assumptions of management in light of its experience, perception of historical trends, and results of the PFS, but such statements are not guarantees of future performance. In particular, this news release contains forward-looking information relating to: the estimated mineral resources and mineral resources at the Clearwater Project; expectations regarding the PFS, including statements regarding the results of the PFS and interpretations thereof; expectations concerning the Clearwater Project, including extraction, production, pretreatment, purification, volume reduction and conversion process and features and the expected outcomes thereof; the expected economic performance of the Clearwater Project, including capital costs, operating costs, water usage, land use and carbon emissions; statements regarding the Company's strategy for minimizing environmental impact and liquid waste and maximizing water reuse, with no planned tailings or waste piles; the potential for a secondary revenue stream should the Company be able to sell the calcium carbonate generated during the production of lithium hydroxide; plans and objectives of management for the Company's operations and the Clearwater Project; and the inherent hazards associated with mineral exploration and mining operations. In preparing the forward-looking information in this news release, the Company has applied several material assumptions, including, but not limited to, that any additional financing needed will be available on reasonable terms; the exchange rates for the U.S. and Canadian currencies will be consistent with the Company's expectations; that the current exploration, development, environmental and other objectives concerning the Clearwater Project can be achieved and that its other corporate activities will proceed as expected; that the current price and demand for lithium will be sustained or will improve; that general business and economic conditions will not change in a materially adverse manner and that all necessary governmental approvals for the planned activities on the Clearwater Project will be obtained in a timely manner and on acceptable terms; the continuity of the price of lithium. All forward-looking information (including future-orientated financial information) is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of mineral exploration and development, fluctuating commodity prices, the effectiveness and feasibility of emerging lithium extraction technologies which have not yet been tested or proven on a commercial scale or on the Company's brine, risks related to the availability of financing on commercially reasonable terms and the expected use of proceeds; operations and contractual obligations; changes in estimated mineral reserves or mineral resources; future prices of lithium and other metals; availability of third party contractors; availability of equipment; failure of equipment to operate as anticipated; accidents, effects of weather and other natural phenomena and other risks associated with the mineral exploration industry; the Company's lack of operating revenues; currency fluctuations; risks related to dependence on key personnel; estimates used in financial statements proving to be incorrect; competitive risks and the availability of financing, as described in more detail in our recent securities filings available under the Company's profile on SEDAR+ at Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
Business Wire
36 minutes ago
- Business Wire
MaxLinear and Comtrend Announce Availability of EV Charging Station Powerline Data Modules
CARLSBAD, Calif.--(BUSINESS WIRE)--MaxLinear, Inc. (Nasdaq: MXL) and Comtrend announced today the availability of ITU-T standards-based powerline data modules for EV Charging Stations (EVSE) backend communication, including data centers and smart parking extensions. Using MaxLinear technology (data-over-powerline), Comtrend's innovative powerline data module series collects and transfers data from power meters in EV charging infrastructure (EVSE) and IoT devices without the need for new cable installations. Comtrend leverages existing electrical powerlines for data communication, providing a scalable and hassle-free solution. This approach is particularly effective in underground concrete environments, where charging stations are frequently installed and other technologies lack reliability. Comtrend PM 1540 key benefits include: - No new wiring required – uses existing electrical wires for data transmission. - Lower latency, higher speeds, and greater stability than traditional methods. - Real-time connectivity. - Significant cost savings vs. LAN, Wi-Fi, or 4G solutions. - Simplified installation — reduced complexity, time, and no need for additional infrastructure. - Supports an electric wire domain of up to 250 nodes for large-scale deployments. - Strong signal transmission reaching up to 700 meters with up to 16 levels of signal repetition. For additional information on the Comtrend PM 1540: Watch the overview video Download the datasheet 'The electric vehicle industry has grown at an unprecedented rate in recent years. We are thrilled to partner with Comtrend to accelerate the installation of EV charging stations, addressing the industry's needs and meeting the rapidly increasing demand,' said Vikas Choudhary, Vice President of Connectivity and Storage Business at MaxLinear. Our product portfolio addresses a wide range of applications, including industrial IoT and Smart Grids, to proactively support the digital transformation of the industry.' 'Comtrend's Powerline Data Modules, powered by MaxLinear's cutting-edge technology, provide high-speed, secure, and reliable wired communication between EV charging stations and the smart grid,' said Vaclav Slehofer, Managing Director and Vice President of Comtrend Europe. 'By partnering with MaxLinear, we're bringing to market a cost-effective, easy-to-deploy and future-ready solution that ensures robust data connectivity for the evolving landscape of smart EV charging infrastructure.' Why MaxLinear for EV Charging? The versatility of the technology standard provides ultra-fast and reliable network connectivity for a wide range of markets and applications. works over any wiring infrastructure – coax, telephone wire, powerline, or Power-over-Fiber (POF). achieves very low latency while enforcing comprehensive Quality of Service (QoS) and delivering Gigabit speeds under any packet size. MaxLinear's baseband processors and analog front-end chipsets are fully ITU compliant and deliver physical data rates up to 2Gbps, the fastest performance in the industry. Deploying MaxLinear for EV charging stations enables seamless interoperability, efficiency, and low-cost deployments. Visit for an overview of MaxLinear's solutions. Why Comtrend for EV Charging? Comtrend EVSE solutions provide enhanced interoperability, integrating with various EV charging brands and smart grid systems, ensuring compatibility across different platforms and technologies. Comtrend's products are available now. For a full overview of Comtrend solutions for EV charging and other industrial IoT solutions, click here for more information. About MaxLinear, Inc. MaxLinear, Inc. (Nasdaq: MXL) is a leading provider of radio frequency (RF), analog, digital, and mixed-signal integrated circuits for access and connectivity, wired and wireless infrastructure, and industrial and multimarket applications. MaxLinear is headquartered in Carlsbad, California. For more information, please visit About Comtrend Comtrend has over 30 years of experience delivering high-quality broadband networking solutions to Service Providers. Comtrend offers a comprehensive lineup of solutions ranging from gateways to networking devices that provide clever coverage to innovative use cases or difficult-to-reach areas. Contact us today to learn more at Comtrend is a Member of the HomeGrid Forum. Cautionary Note About Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others, statements concerning or implying future financial performance, statements relating to MaxLinear's technology and the functionality, performance and benefits of such technology, statements about the potential market opportunity and rate of growth for MaxLinear's technology, statements relating to the partnership between MaxLinear and Comtrend, statements by our Vice President of Connectivity and Storage business and statements by the Managing Director and Vice President of Comtrend Europe. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements and our future financial performance and operating results forecasts generally. Forward-looking statements are based on management's current, preliminary expectations and are subject to various risks and uncertainties. In particular, our future operating results are substantially dependent on our assumptions about market trends and conditions. Additional risks and uncertainties affecting our business, future operating results and financial condition include, without limitation; risks relating to the development, testing, and commercial introduction of new products and product functionalities; risks relating to our relationship with Comtrend; risks relating to our terminated merger with Silicon Motion and related arbitration and class action complaint and the risks related to potential payment of damages; the effect of intense and increasing competition; increased tariffs, export controls or imposition of other trade barriers; impacts of global economic conditions; the cyclical nature of the semiconductor industry; a significant variance in our operating results and impact on volatility in our stock price, and our ability to sustain our current level of revenue, which has previously declined, and/or manage future growth effectively, and the impact of excess inventory in the channel on our customers' expected demand for certain of our products and on our revenue; escalating trade wars, military conflicts and other geopolitical and economic tensions among the countries in which we conduct business; our ability to obtain or retain government authorization to export certain of our products or technology; risks related to the loss of, or a significant reduction in orders from major customers; costs of legal proceedings or potential violations of regulations; information technology failures; a decrease in the average selling prices of our products; failure to penetrate new applications and markets; development delays and consolidation trends in our industry; inability to make substantial research and development investments; delays or expenses caused by undetected defects or bugs in our products; substantial quarterly and annual fluctuations in our revenue and operating results; failure to timely develop and introduce new or enhanced products; order and shipment uncertainties; failure to accurately predict our future revenue and appropriately budget expenses; lengthy and expensive customer qualification processes; customer product plan cancellations; failure to maintain compliance with government regulations; failure to attract and retain qualified personnel; any adverse impact of rising interest rates on us, our customers, and our distributors and related demand; risks related to compliance with privacy, data protection and cybersecurity laws and regulations; risks related to conforming our products to industry standards; risks related to business acquisitions and investments; claims of intellectual property infringement; our ability to protect our intellectual property; risks related to security vulnerabilities of our products; use of open source software in our products; and failure to manage our relationships with, or negative impacts from, third parties. In addition to these risks and uncertainties, investors should review the risks and uncertainties contained in our filings with the Securities and Exchange Commission, including our Current Reports on Form 8-K, as well as the information to be set forth under the caption "Risk Factors" in MaxLinear's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. All forward-looking statements are based on the estimates, projections and assumptions of management as of the date of this press release, and MaxLinear is under no obligation (and expressly disclaims any such obligation) to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.
Business Wire
an hour ago
- Business Wire
Circus SE Moves Global Headquarters to Munich
MUNICH--(BUSINESS WIRE)--Circus SE (XETRA: CA1), a global technology company in AI software and autonomous robotics for the food service industry, today announces the relocation of its global headquarters to Munich, marking a strategic move to strengthen its position in one of Europe's most dynamic technology hubs. With a strong foundation already laid in the region through years of mechanical engineering and robotics development, the company is doubling down on Munich as its core location for AI innovation, advanced robotics, and pre-series production of its new CA-M military-grade autonomous robot platform. 'As OpenAI, NVIDIA and other global leaders invest in Munich and the global demand for intelligent automation surges, Munich has become one of the few places in the world where cutting-edge research meets world-class engineering talent,' said Nikolas Bullwinkel, CEO and Founder of Circus. 'We're building the future of robotics here – from our civilian food service automation to next-gen defense solutions – and Munich will be our long-term launchpad.' The new HQ will serve as a central R&D hub, attracting top talent and enabling closer collaboration with leading universities, research centers, and the region's industrial base. 'The ecosystem in Munich is continuously evolving into a global hotspot for robotics and AI,' says Dr. Arne Rost, member of the Circus Advisory Board Member and Managing Director of the Venture Lab Robotics/AI from the Technical University Munich. 'The city brings together academic excellence, entrepreneurial drive, and international deep-tech talent – and Circus is one of the most ambitious companies actively shaping this ecosystem.' Circus' expansion signals a broader trend of global tech players choosing Munich as their base to scale high-impact innovation. With serial production underway and global deployments of its robotics system CA-1 lined up, Circus is set to redefine how intelligent machines integrate into everyday life — and Munich is where that future begins. About Circus SE Circus SE (XETRA: CA1) is a global technology company in the field of embodied AI and AI software for the food service industry, driving innovation and autonomy in labor-intensive sectors. With its core product, the CA-1 robot, Circus is a pioneer in applying embodied AI, integrating cutting-edge technologies into real-world operations, and transforming the food service industry. By combining advanced robotics, AI-driven software, and a mission to solve global challenges, Circus is shaping the future of autonomous systems and redefining human-AI collaboration. Headquartered in Germany and with a rapidly growing international presence, Circus leads the next generation of AI applications.
